Myriam Alcalay

Myriam Alcalay

Auto-generated profile, based on publicly available information

Myriam Alcalay

Department of Experimental Oncology, European Institute of Oncology IRCCS, Milano, Italy

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2005 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
‪‪‪Brunangelo ‪Falini
‪Brunangelo ‪Falini
CMCristina Mecucci
Cristina Mecucci
ETEnrico Tiacci
Enrico Tiacci
MAMyriam Alcalay
Myriam Alcalay
RRRoberto Rosati
Roberto Rosati
MMMassimo F. Martelli
Massimo F. Martelli
Nucleophosmin (NPM), a nucleocytoplasmic shuttling protein with prominent nucleolar localization, regulates the ARF-p53 tumor-suppressor pathway. Translocations involving the NPM gene cause cytoplasmic dislocation of the NPM protein. We used immunohistochemical methods to study the subcellular localization of NPM in bone marrow–biopsy specimens from 591 patients with primary acute myelogenous leukemia (AML). We then correlated the presence of cytoplasmic NPM with clinical and biologic features of the disease. Cytoplasmic NPM was detected in 208 (35.2 percent) of the 591 specimens from patients with primary AML but not in 135 secondary AML specimens or in 980 hematopoietic or extrahematopoietic neoplasms other than AML. It was associated with a wide spectrum of morphologic subtypes of the disease, a normal karyotype, and responsiveness to induction chemotherapy, but not with recurrent genetic abnormalities. There was a high frequency of FLT3 internal tandem duplications and absence of CD34 and CD133 in AML specimens with a normal karyotype and cytoplasmic dislocation of NPM, but not in those in which the protein was restricted to the nucleus. AML specimens with cytoplasmic NPM carried mutations of the NPM gene that were predicted to alter the protein at its C-terminal; this mutant gene caused cytoplasmic localization of NPM in transfected cells. Cytoplasmic NPM is a characteristic feature of a large subgroup of patients with AML who have a normal karyotype, NPM gene mutations, and responsiveness to induction chemotherapy.

1 August 1993 in Cell
Verified
Journal Article
Closed access
FGFrancesco Grignani
Francesco Grignani
FFFerrucci Francesco
Ferrucci Francesco
Ugo TestaUgo Testa
Ugo Testa
GTGiampaolo Talamo
Giampaolo Talamo
MFMarta Fagioli
Marta Fagioli
PPPier Giuseppe Pelicci
Pier Giuseppe Pelicci

18 March 1997 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DBDiane Brown
Diane Brown
SKScott Kogan
Scott Kogan
ELEric Lagasse
Eric Lagasse
IWIrving Weissman
Irving Weissman
MAMyriam Alcalay
Myriam Alcalay
JBJ. Michael Bishop
J. Michael Bishop
The malignant cells of acute promyelocytic leukemia (APL) contain a reciprocal chromosomal translocation that fuses the promyelocytic leukemia gene (PML) with the retinoic acid receptor α gene (RARα). To test the hypothesis that the chimeraPMLRARα plays a role in leukemogenesis, we expressed aPMLRARα cDNA in myeloid cells of transgenic mice.PMLRARα transgenic mice exhibited impaired neutrophil maturation early in life, which progressed at a low frequency over the course of several months to overt APL. Both the preleukemic state and the leukemia could be transplanted to nontransgenic mice, and the transplanted preleukemia could progress to APL. The APL recapitulated features of the human disease, including a response to retinoic acid. Retinoic acid caused the leukemic cells to differentiatein vitroandin vivo, eliciting remissions of both the preleukemic state and APL in mice. Our results demonstrate thatPMLRARα impairs neutrophil differentiation and initiates the development of APL. The transgenic mice described here provide an apparently accurate model for human APL that includes clear evidence of tumor progression. The model should be useful for exploring the molecular pathogenesis of APL and the mechanisms of the therapeutic response to retinoic acid, as well as for preclinical studies of therapeutic regimens.

1 August 2005 in Blood
Verified
Journal Article
Closed access
PDF file
MAMyriam Alcalay
Myriam Alcalay
ETEnrico Tiacci
Enrico Tiacci
RBRoberta Bergomas
Roberta Bergomas
BBBarbara Bigerna
Barbara Bigerna
EVElisa Venturini
Elisa Venturini
PPPier Giuseppe Pelicci
Pier Giuseppe Pelicci
Approximately one third of acute myeloid leukemias (AMLs) are characterized by aberrant cytoplasmic localization of nucleophosmin (NPMc+ AML), consequent to mutations in the NPM putative nucleolar localization signal. These events are mutually exclusive with the major AML-associated chromosomal rearrangements, and are frequently associated with normal karyotype, FLT3 mutations, and multilineage involvement. We report the gene expression profiles of 78 de novo AMLs (72 with normal karyotype; 6 without major chromosomal abnormalities) that were characterized for the subcellular localization and mutation status of NPM. Unsupervised clustering clearly separated NPMc+ from NPMc– AMLs, regardless of the presence of FLT3 mutations or non–major chromosomal rearrangements, supporting the concept that NPMc+ AML represents a distinct entity. The molecular signature of NPMc+ AML includes up-regulation of several genes putatively involved in the maintenance of a stem-cell phenotype, suggesting that NPMc+ AML may derive from a multipotent hematopoietic progenitor.

1 January 2009 in Nature
Verified
Journal Article
Closed access
PDF file
AVAndrea Viale
Andrea Viale
FFFrancesca De Franco
Francesca De Franco
AOAnnette Orleth
Annette Orleth
VCValeria Cambiaghi
Valeria Cambiaghi
VGVirginia Giuliani
Virginia Giuliani
PPPier Giuseppe Pelicci
Pier Giuseppe Pelicci

1 July 2007 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
SSSilvia Senese
Silvia Senese
KZKatrin Zaragoza
Katrin Zaragoza
SMSimone Minardi
Simone Minardi
IMIvan Muradore
Ivan Muradore
SRSimona Ronzoni
Simona Ronzoni
SCSusanna Chiocca
Susanna Chiocca
Posttranslational modifications of core histones are central to the regulation of gene expression. Histone deacetylases (HDACs) repress transcription by deacetylating histones, and class I HDACs have a crucial role in mouse, Xenopus laevis, zebra fish, and Caenorhabditis elegans development. The role of individual class I HDACs in tumor cell proliferation was investigated using RNA interference-mediated protein knockdown. We show here that in the absence of HDAC1 cells can arrest either at the G(1) phase of the cell cycle or at the G(2)/M transition, resulting in the loss of mitotic cells, cell growth inhibition, and an increase in the percentage of apoptotic cells. On the contrary, HDAC2 knockdown showed no effect on cell proliferation unless we concurrently knocked down HDAC1. Using gene expression profiling analysis, we found that inactivation of HDAC1 affected the transcription of specific target genes involved in proliferation and apoptosis. Furthermore, HDAC2 downregulation did not cause significant changes compared to control cells, while inactivation of HDAC1, HDAC1 plus HDAC2, or HDAC3 resulted in more distinct clusters. Loss of these HDACs might impair cell cycle progression by affecting not only the transcription of specific target genes but also other biological processes. Our data support the idea that a drug targeting specific HDACs could be highly beneficial in the treatment of cancer.